NCT06481228View on ClinicalTrials.gov

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

NARecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2028

Conditions
Philadelphia Positive Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, Adult
Interventions
COMBINATION_PRODUCT

CAR-T cells

CAR-T cells as consolidation therapy

DRUG

Venetoclax

BCL2 inhibitor

DRUG

Olverembatinib

TKI

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER